These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 36068782)

  • 1. Towards a precision immune checkpoint blockade immunotherapy in patients with colorectal cancer: Strategies and perspectives.
    Cui G
    Biomed Pharmacother; 2022 May; 149():112923. PubMed ID: 36068782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer.
    Picard E; Verschoor CP; Ma GW; Pawelec G
    Front Immunol; 2020; 11():369. PubMed ID: 32210966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploring immunotherapy in colorectal cancer.
    Weng J; Li S; Zhu Z; Liu Q; Zhang R; Yang Y; Li X
    J Hematol Oncol; 2022 Jul; 15(1):95. PubMed ID: 35842707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RTP4 silencing provokes tumor-intrinsic resistance to immune checkpoint blockade in colorectal cancer.
    Yamamoto Y; Shimada S; Akiyama Y; Tsukihara S; Sugimoto R; Kabashima A; Tokunaga M; Kinugasa Y; Kawakami Y; Tanaka S
    J Gastroenterol; 2023 Jun; 58(6):540-553. PubMed ID: 36859628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy of microsatellite stable colorectal cancer: resistance mechanisms and treatment strategies.
    Han YJ; Shao CY; Yao Y; Zhang Z; Fang MZ; Gong T; Zhang YJ; Li M
    Postgrad Med J; 2024 May; 100(1184):373-381. PubMed ID: 38211949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An update on the use of immunotherapy in patients with colorectal cancer.
    Nguyen M; Tipping Smith S; Lam M; Liow E; Davies A; Prenen H; Segelov E
    Expert Rev Gastroenterol Hepatol; 2021 Mar; 15(3):291-304. PubMed ID: 33138649
    [No Abstract]   [Full Text] [Related]  

  • 7. An integrative in-silico analysis discloses a novel molecular subset of colorectal cancer possibly eligible for immune checkpoint immunotherapy.
    Sibilio P; Belardinilli F; Licursi V; Paci P; Giannini G
    Biol Direct; 2022 May; 17(1):10. PubMed ID: 35534873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current status and perspectives of immune checkpoint inhibitors for colorectal cancer.
    Hirano H; Takashima A; Hamaguchi T; Shida D; Kanemitsu Y;
    Jpn J Clin Oncol; 2021 Jan; 51(1):10-19. PubMed ID: 33205813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Defining the current role of immune checkpoint inhibitors in the treatment of mismatch repair-deficient/microsatellite stability-high colorectal cancer and shedding light on future approaches.
    Tan E; Sahin IH
    Expert Rev Gastroenterol Hepatol; 2021 Jul; 15(7):735-742. PubMed ID: 33539189
    [No Abstract]   [Full Text] [Related]  

  • 10. Immune Checkpoint Inhibition in Colorectal Cancer: Microsatellite Instability and Beyond.
    Cohen R; Rousseau B; Vidal J; Colle R; Diaz LA; André T
    Target Oncol; 2020 Feb; 15(1):11-24. PubMed ID: 31786718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Emergence of Immune-checkpoint Inhibitors in Colorectal Cancer Therapy.
    Ghidini M; Fusco N; Salati M; Khakoo S; Tomasello G; Petrelli F; Trapani D; Petrillo A
    Curr Drug Targets; 2021; 22(9):1021-1033. PubMed ID: 33563194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microsatellite Instability as a Predictor of Outcomes in Colorectal Cancer in the Era of Immune-Checkpoint Inhibitors.
    Lengyel CG
    Curr Drug Targets; 2021; 22(9):968-976. PubMed ID: 33970843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I-Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications.
    Marginean EC; Melosky B
    Arch Pathol Lab Med; 2018 Jan; 142(1):17-25. PubMed ID: 29144791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modeling resistance of colorectal peritoneal metastases to immune checkpoint blockade in humanized mice.
    Küçükköse E; Heesters BA; Villaudy J; Verheem A; Cercel M; van Hal S; Boj SF; Borel Rinkes IHM; Punt CJA; Roodhart JML; Laoukili J; Koopman M; Spits H; Kranenburg O
    J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36543378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Crosstalk Between the MSI Status and Tumor Microenvironment in Colorectal Cancer.
    Lin A; Zhang J; Luo P
    Front Immunol; 2020; 11():2039. PubMed ID: 32903444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune Checkpoint Blockade Therapy in Patients With Colorectal Cancer Harboring Microsatellite Instability/Mismatch Repair Deficiency in 2022.
    André T; Cohen R; Salem ME
    Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-9. PubMed ID: 35471834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advancing immune checkpoint blockade in colorectal cancer therapy with nanotechnology.
    Liu Z; Xiang Y; Zheng Y; Kang X
    Front Immunol; 2022; 13():1027124. PubMed ID: 36341334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current Microsatellite Instability Testing in Management of Colorectal Cancer.
    Sun BL
    Clin Colorectal Cancer; 2021 Mar; 20(1):e12-e20. PubMed ID: 32888812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transforming Albumin into a Trojan Horse of Immunotherapy-Resistant Colorectal Cancer with a High Microsatellite Instability.
    Yang W; Li Z; Li Y; He W; Yan J
    ACS Nano; 2024 Jul; 18(29):19332-19344. PubMed ID: 38990329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting MSS colorectal cancer with immunotherapy: are we turning the corner?
    Wang C; Fakih M
    Expert Opin Biol Ther; 2021 Oct; 21(10):1347-1357. PubMed ID: 34030532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.